Reminyl, Amaryl Name Confusion Concerns ISMP
This article was originally published in The Pink Sheet Daily
Executive Summary
Confusion between the antidiabetic Amaryl and the Alzheimer’s medication Reminyl has resulted in medication errors, the Institute for Safe Medication Practices says. ISMP is working with FDA, Aventis and Janssen to develop a solution.
You may also be interested in...
Janssen To Change Name Of Reminyl Products
Janssen agreed to change the brand name for galantamine products due to continued confusion with Aventis' Amaryl, which has resulted in medication errors. The company will submit new proposed names to FDA for review.
Janssen To Change Name Of Reminyl Products
Janssen agreed to change the brand name for galantamine products due to continued confusion with Aventis' Amaryl, which has resulted in medication errors. The company will submit new proposed names to FDA for review.
Janssen Reminyl Medication Error Campaign Includes Patient Brochure
The company launched the campaign after receiving reports of 10 medication errors, including two deaths due to confusion with Aventis' Amaryl. The plan includes journal ads, pharmacy shelf tags and pop-up pharmacy computer alerts.